checkAd

Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies

Xlife Sciences AG / Key word(s): Miscellaneous
Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies

01.12.2022 / 07:01 CET/CEST


Lysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Sciences and curasan (a leading global provider of biomaterials for bone and tissue regeneration in dental and orthopedic surgery), signed an exclusive license agreement. Novaxomx has obtained the exclusive rights to use Lysatpharma’s patented “exosome” technology for the research of optimizing biomimetic osteoconductive carrier materials by biologizing them with exosomes.

Novaxomx focuses on the research, development, certification, production, and marketing of disruptive, biosurgical therapies for use in musculoskeletal diseases and tissue regeneration. It’s ambition is to improve the carriers’ biofunctionality in regenerative processes such as non-union or delayed non-union fractures or bone fusion after spinal fusion procedures. Other possible applications include the treatment of chronic osteomyelitis, rheumatoid arthritis, or periodontal bone loss.

The bioactive nanovesicles are secreted from human stem cells or derived from autologous platelets. They are introduced with the carrier materials and enable intercellular communication, which is crucial for regenerative processes in the human body.

Frank Plöger, Chief Scientific Officer of Xlife Sciences AG and Managing Director of Lysatpharma GmbH, says: “Xlife Sciences and curasan founded Novaxomx in March 2022. Since then, we made already valuable progress, resulting in the licence agreement we announced today. We look forward to continuing to work on this promising R&D project, aiming at improve patients lives. Furthermore, the agreement is also another proofpoint of the continuously increasing number of research projects and achieved synergies within the broad Xlife universe.”

Seite 1 von 3


Wertpapier



0 Kommentare
Nachrichtenquelle: EQS Group AG
 |  104   |   |   

Schreibe Deinen Kommentar

Disclaimer

Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies Xlife Sciences AG / Key word(s): Miscellaneous Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies 01.12.2022 / 07:01 CET/CEST Lysatpharma, a portfolio company of …

Nachrichten des Autors

688 Leser
356 Leser
356 Leser
320 Leser
284 Leser
964 Leser
688 Leser
640 Leser
496 Leser
472 Leser
1360 Leser
1224 Leser
1132 Leser
1056 Leser
976 Leser
2385 Leser
2343 Leser
2247 Leser
2237 Leser
2225 Leser